A293780 Stock Overview
AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AptaBio Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,360.00 |
| 52 Week High | ₩13,330.00 |
| 52 Week Low | ₩4,935.00 |
| Beta | 2.01 |
| 1 Month Change | -10.80% |
| 3 Month Change | -7.69% |
| 1 Year Change | -40.11% |
| 3 Year Change | -78.66% |
| 5 Year Change | n/a |
| Change since IPO | -67.30% |
Recent News & Updates
Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money
Mar 26
Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?
Feb 23
Shareholder Returns
| A293780 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 8.2% | 2.9% | 2.7% |
| 1Y | -40.1% | 10.0% | 5.8% |
Return vs Industry: A293780 underperformed the KR Biotechs industry which returned 10% over the past year.
Return vs Market: A293780 underperformed the KR Market which returned 5.8% over the past year.
Price Volatility
| A293780 volatility | |
|---|---|
| A293780 Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A293780 has not had significant price volatility in the past 3 months.
Volatility Over Time: A293780's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Jin Soo | www.aptabio.com |
AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH).
AptaBio Therapeutics Inc. Fundamentals Summary
| A293780 fundamental statistics | |
|---|---|
| Market cap | ₩141.82b |
| Earnings (TTM) | -₩19.10b |
| Revenue (TTM) | ₩323.87m |
437.9x
P/S Ratio-7.4x
P/E RatioIs A293780 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A293780 income statement (TTM) | |
|---|---|
| Revenue | ₩323.87m |
| Cost of Revenue | ₩262.80m |
| Gross Profit | ₩61.06m |
| Other Expenses | ₩19.16b |
| Earnings | -₩19.10b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -856.45 |
| Gross Margin | 18.85% |
| Net Profit Margin | -5,896.78% |
| Debt/Equity Ratio | 25.0% |
How did A293780 perform over the long term?
See historical performance and comparison